Evidence map›Paper›PMID 40450144›Full record

SynthesisEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2025

Effectiveness and safety of camrelizumab plus apatinib in treating recurrent/metastatic nasopharyngeal carcinoma: a single-arm meta-analysis.

Yanmei Li, Yongfu Liang, Peichang Ye, Guoan Chen, Yimin Zhang, Meixia Chen, Wenhua Xiong, Xiuhao Yang, Xiaowen Zhang

Abstract readMeta-AnalysisReview
PubMed Publisher
In one paragraph

Synthesis in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yanmei LiDepartment of Otorhinolaryngology, The Fifth People's Hospital of Nanhai District, Foshan, 528231, Guangdong, China.
Yongfu LiangOphthalmology Department, The Fifth People's Hospital of Nanhai District, Foshan, 528231, Guangdong, China.
Peichang YeDepartment of Otorhinolaryngology, Guangzhou Development District Hospital, Foshan, 510700, Guangdong, China.
Guoan ChenOphthalmology Department, The Fifth People's Hospital of Nanhai District, Foshan, 528231, Guangdong, China.
Yimin ZhangDepartment of Otorhinolaryngology, The Fifth People's Hospital of Nanhai District, Foshan, 528231, Guangdong, China.
Meixia ChenOphthalmology Department, The Fifth People's Hospital of Nanhai District, Foshan, 528231, Guangdong, China.
Wenhua XiongDepartment of Otorhinolaryngology, The Fifth People's Hospital of Nanhai District, Foshan, 528231, Guangdong, China.
Xiuhao YangDepartment of Otorhinolaryngology, The Fifth People's Hospital of Nanhai District, Foshan, 528231, Guangdong, China.
Xiaowen ZhangDepartment of Otorhinolaryngology - Head and Neck Surgery, the First Affiliated Hospital of Guangzhou Medical University, 151 Yanjiang Road, Guangzhou, 510120, Guangdong, China. ENTyanmei@126.com.ORCID http://orcid.org/0009-0003-5838-9143

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the efficacy and safety of camrelizumab combined with apatinib in the treatment of recurrent/metastatic nasopharyngeal carcinoma (RM-NPC) and provide a basis for clinical application.

methodsPubMed, Cochrane Library, Embase, and Web of Science databases were searched until July 19, 2024 for relevant studies. Data extraction and risk of bias assessment were conducted. Meta-analysis was performed using R software.

resultsFour single-arm trials with a total of 205 patients were included, with an overall survival rate of 78%, a progression-free survival rate of 45%, an objective response rate of 60%, and a disease control rate of 76%. Common adverse reactions were anemia (45%), leukopenia (46%), and fatigue (53%). The incidence of grade 3 or above adverse reactions was less than 10%, except for hypertension (16%).

conclusionCamrelizumab combined with apatinib showed favorable efficacy and safety in the treatment of RM-NPC, providing an important reference for clinical treatment strategies.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsNasopharyngeal CarcinomaNasopharyngeal NeoplasmsNeoplasm Recurrence, LocalPyridinesAntineoplastic AgentsHumansTreatment OutcomeAntibodies, Monoclonal, HumanizedAntineoplastic AgentsapatinibcamrelizumabPyridinesApatinibCamrelizumabMeta-analysisNasopharyngeal carcinoma

Identifiers

PMID40450144

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.